Paradigm Therapeutics, Genmab to Develop Antibody Tx | GenomeWeb

NEW YORK, April 11 - Genmab and Paradigm Therapeutics today said they plan to co-develop new antibody therapeutics.

The partners will combine Paradigm's disease targets and bioinformatics platform with Genmab's fully human antibody technology to develop therapeutics for cancer, inflammatory diseases, and other states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.